Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 7/20 | 0.59 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.58 |
| ▸ | PIM1 | P11309 | 1/20 | 0.58 |
| ▸ | GSK3B | P49841 | 1/20 | 0.58 |
| ▸ | CTNNB1 | P35222 | 3/20 | 0.57 |
| ▸ | WNT3A | P56704 | 3/20 | 0.57 |
| ▸ | MAOA | P21397 | 1/20 | 0.55 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.55 |
| ▸ | NPC1 | O15118 | 3/20 | 0.55 |
| ▸ | RAB9A | P51151 | 3/20 | 0.55 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.55 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.55 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.55 |
| ▸ | CLK2 | P49760 | 1/20 | 0.55 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.55 |
| ▸ | PRKG1 | Q13976 | 1/20 | 0.55 |
| ▸ | PRKD2 | Q9BZL6 | 1/20 | 0.55 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.55 |
| ▸ | SGK2 | Q9HBY8 | 1/20 | 0.55 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19391342 | 0.88 | ROCK2 (0.63) | MAOBROCK2PIM1GSK3BCTNNB1 | |
| SCHEMBL4154121 | 0.87 | MAOB (0.62) | MAOBROCK2PIM1GSK3BNPC1 | |
| SCHEMBL31738598 | 0.87 | MAOB (0.62) | MAOBROCK2PIM1GSK3BNPC1 | |
| SCHEMBL3493150 | 0.84 | MAOB (0.59) | MAOBROCK2CTNNB1WNT3AMAOA | |
| SCHEMBL19086030 | 0.83 | MAOB (0.62) | MAOBROCK2CTNNB1WNT3AMAOA | |
| SCHEMBL5418713 | 0.83 | ROCK2 (0.58) | MAOBROCK2CTNNB1WNT3AMAOA | |
| SCHEMBL27836079 | 0.83 | MAOB (0.58) | MAOBROCK2CTNNB1WNT3AMAOA | |
| SCHEMBL5425713 | 0.83 | MAOB (0.55) | MAOBROCK2CTNNB1WNT3AMAOA | |
| SCHEMBL122504 | 0.81 | ROCK2 (0.64) | MAOBROCK2CTNNB1WNT3AMAOA | |
| SCHEMBL29521387 | 0.81 | ROCK2 (0.64) | MAOBROCK2CTNNB1WNT3AMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4149945-A1 | SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | Arbutus Biopharma Corporation (CA) | 2023-03-22 | — | — | EP | claimed |
| WO-2016041618-A1 | SUBSTITUTED INDAZOLES AND RELATED HETEROCYCLES | MERCK PATENT GMBH (DE) | 2016-03-24 | — | — | WO | claimed |
| US-20230312481-A1 | SUBSTITUTED (PHTHALAZIN-1-YLMETHYL)UREAS, SUBSTITUTED N-(PHTHALAZIN-1-YLMETHYL)AMIDES, AND ANALOGUES THEREOF | ARBUTUS BIOPHARMA CORP (CA) | 2023-10-05 | — | — | US | disclosed |
| EP-4149945-A1 | SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | Arbutus Biopharma Corporation (CA) | 2023-03-22 | — | — | EP | disclosed |
| CN-115551864-A | Substituted tricyclic amides, analogs thereof, and methods of using the same | 爱彼特生物制药公司 | 2022-12-30 | — | — | CN | disclosed |
| WO-2016041618-A1 | SUBSTITUTED INDAZOLES AND RELATED HETEROCYCLES | MERCK PATENT GMBH (DE) | 2016-03-24 | — | — | WO | disclosed |
| US-7199147-B2 | Rho kinase inhibitors | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-04-03 | — | — | US | disclosed |
| US-20040138286-A1 | Rho kinase inhibitors | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2004-07-15 | — | — | US | disclosed |
| EP-1403255-A1 | Rho KINASE INHIBITORS | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2004-03-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138286-A1 | Rho kinase inhibitors | ROCK1, ROCK2, ARHGDIA | MAOB 2025/4885ROCK2 2/4885PIM1 760/4885 |
| US-20230312481-A1 | SUBSTITUTED (PHTHALAZIN-1-YLMETHYL)UREAS, SUBSTITUTED N-(PHTHALAZIN-1-YLMETHYL)AMIDES, AND ANALOGUES THEREOF | NSD3, PML, NSD1 | MAOB 4105/4885ROCK2 4478/4885PIM1 3270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.